Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).

Hayashi T, Uemura Y, Kumagai M, Kimpara M, Kanno H, Ohashi Y; MIRACLE-CKD Study Group.

Clin Exp Nephrol. 2019 Mar;23(3):349-361. doi: 10.1007/s10157-018-1649-0. Epub 2018 Oct 5.

2.

Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.

Fuller DS, Robinson BM, Locatelli F, Pisoni RL.

Nephron. 2018;140(1):24-30. doi: 10.1159/000490202. Epub 2018 Jun 26.

4.

Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.

Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):907.

5.

Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.

Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2017 Aug 7;8:CD009904. doi: 10.1002/14651858.CD009904.pub2. Review.

6.

Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.

Amato L, Addis A, Saulle R, Trotta F, Mitrova Z, Davoli M.

J Nephrol. 2018 Jun;31(3):321-332. doi: 10.1007/s40620-017-0419-5. Epub 2017 Jun 23.

PMID:
28646375
7.

Efficacy of C.E.R.A. in Routine Clinical Practice for Correction of Anaemia and Maintenance of the Haemoglobin Levels in CKD Patients not on Dialysis.

Promod PJ, Deshpande R, Mohanty NK, Kulkarni S, Shah HA, Ganju A, Kukreja A, Joshi S.

J Assoc Physicians India. 2017 Mar;65(3):52-57.

PMID:
28462544
8.

Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.

Peters NO, Jay N, Cridlig J, Rostoker G, Frimat L.

BMC Nephrol. 2017 Mar 20;18(1):97. doi: 10.1186/s12882-017-0513-x.

9.

Fixed dose of long-acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis.

Liu WS, Chu DC, Chan HL, Li SY, Liu CK, Yang CY, Chen YW, Lee PC, Lai YT, Lin CC.

Clin Exp Pharmacol Physiol. 2016 Oct;43(10):875-82. doi: 10.1111/1440-1681.12618.

PMID:
27385380
10.
11.

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.

Honda H, Kobayashi Y, Onuma S, Shibagaki K, Yuza T, Hirao K, Yamamoto T, Tomosugi N, Shibata T.

PLoS One. 2016 Mar 15;11(3):e0151601. doi: 10.1371/journal.pone.0151601. eCollection 2016.

12.

Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.

Locatelli F, Choukroun G, Truman M, Wiggenhauser A, Fliser D.

Adv Ther. 2016 Apr;33(4):610-25. doi: 10.1007/s12325-016-0309-6. Epub 2016 Mar 10.

13.

Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.

Schmid H.

Expert Rev Hematol. 2016 Jan;9(1):5-20. doi: 10.1586/17474086.2016.1112734. Epub 2015 Nov 17. Review.

PMID:
26573694
14.

[Switch of methoxy-polyethylene-glycol-epoetin beta to darbepoetin alfa in 263 dialysis patients].

Rieger J, Krummel T, Petitjean P, Chantrel F, Dimitrov Y.

Ann Pharm Fr. 2016 Jan;74(1):45-8. doi: 10.1016/j.pharma.2015.06.005. Epub 2015 Jul 17. French.

PMID:
26194063
15.

Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.

Otsuka T, Sakai Y, Yui S, Sukegawa M, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Tsuruoka S.

J Nippon Med Sch. 2015;82(1):21-6. doi: 10.1272/jnms.82.21.

16.

Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.

Sánchez-Escuredo A, Batista F, Cases A, Torregrosa JV.

Transplant Proc. 2015 Jan-Feb;47(1):73-5. doi: 10.1016/j.transproceed.2014.12.006.

PMID:
25645774
17.

Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials.

Locatelli F, de Francisco A, Deray G, Fliser D, Armstrong G, Dougherty FC, Ehrhard P.

Nephron Clin Pract. 2014;128(3-4):323-32. doi: 10.1159/000366478. Epub 2014 Dec 5.

18.

A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients.

Toida T, Sato Y, Shibata N, Kitamura K, Fujimoto S.

Blood Purif. 2014;38(3-4):174-9. doi: 10.1159/000368391. Epub 2014 Dec 6.

PMID:
25502179
19.

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF.

Cochrane Database Syst Rev. 2014 Dec 8;(12):CD010590. doi: 10.1002/14651858.CD010590.pub2. Review.

20.

Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.

Alsalimy N, Awaisu A.

Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Epub 2014 Oct 7. Review.

PMID:
25288147

Supplemental Content

Loading ...
Support Center